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Therapeutic coma for status epilepticus
Differing practices in a prospective multicenter study
ABSTRACT
Objective: Our aim was to analyze and compare the use of therapeutic coma (TC) for refractory
status epilepticus (SE) across different centers and its effect on outcome.
Methods: Clinical data for all consecutive adults (.16 years) with SE of all etiologies (except
postanoxic) admitted to 4 tertiary care centers belonging to Harvard Affiliated Hospitals (HAH)
and the Centre Hospitalier Universitaire Vaudois (CHUV) were prospectively collected and ana-
lyzed for TC details, mortality, and duration of hospitalization.
Results: Two hundred thirty-six SE episodes in the CHUV and 126 in the HAH were identified.
Both groups were homogeneous in demographics, comorbidities, SE characteristics, and Status
Epilepticus Severity Score (STESS); TC was used in 25.4% of cases in HAH vs 9.75% in CHUV.
After adjustment, TC use was associated with younger age, lower Charlson Comorbidity Index,
increasing SE severity, refractory SE, and center (odds ratio 11.3 for HAH vs CHUV, 95% con-
fidence interval 2.47–51.7). Mortality was associated with increasing Charlson Comorbidity
Index and STESS, etiology, and refractory SE. Length of stay correlated with STESS, etiology,
refractory SE, and use of TC (incidence rate ratio 1.6, 95% confidence interval 1.22–2.11).
Conclusions: Use of TC for SE treatment seems markedly different between centers from the
United States and Europe, and did not affect mortality considering the whole cohort. However,
TC may increase length of hospital stay and related costs.
Classification of evidence: This study provides Class III evidence that for patients with SE, TC does
not significantly affect mortality. The study lacked the precision to exclude an important effect of
TC on mortality. Neurology® 2016;87:1650–1659
GLOSSARY
ASD 5 antiseizure drug; BZD 5 benzodiazepine; CCI 5 Charlson Comorbidity Index; CHUV 5 Centre Hospitalier Universi-
taire Vaudois; CIVAD5 continuous IV anesthetic drug; HAH5Harvard Affiliated Hospitals; ICU5 intensive care unit; LOS5
length of stay; NCSEC 5 nonconvulsive status epilepticus in coma; ROC 5 receiver operating characteristic; SE 5 status
epilepticus; STESS 5 Status Epilepticus Severity Score; TC 5 therapeutic coma.
Status epilepticus (SE) is a frequent life-threatening neurologic emergency1; rapid and effective
treatment is advocated. Treatment guidelines2,3 recommend a stepwise approach. Randomized
controlled trials4,5 have demonstrated the role of benzodiazepines (BZDs) as initial treatment. If
this fails, guidelines recommend the use of a nonsedative antiseizure drug (ASD), and when SE
is refractory, continuous IV anesthetic drugs (CIVADs) should be considered to induce ther-
apeutic coma (TC), especially in convulsive SE. The available evidence to guide clinical
decision-making is nevertheless of low level.1 The rationale of using TC is to stop seizure activity
to hypothetically prevent seizure-induced brain damage and to reduce cerebral metabolism6;
however, supporting data are missing.7
TC is resource-consuming: it requires an intensive care unit (ICU) and continuous EEG.8
Moreover, CIVADs are related to rare but potentially serious side effects, such as hemodynamic
instability, propofol infusion syndrome, propylene glycol toxicity (a vehicle for many anesthetic
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drugs), and bowel ischemia.9 In the context of
limited evidence supporting the practice of TC
and the unfavorable side-effect profile, recent
retrospective observational studies10–12 sug-
gested that TC may be independently associ-
ated with increased mortality. While these
studies are not yet sufficient to change clinical
practices, they have raised important questions.
Given the current uncertainty, our aim was
to compare different policies of TC use for SE
management, in the sense of a natural experi-
ment, and its potential effect on mortality and
hospital length of stay (LOS), using a prospec-
tive multicenter SE registry.
METHODS Primary research question. The primary aim
was to compare different TC policies across different hospitals
of 2 countries and their potential effect on mortality and on
LOS, with Class III level of evidence.
Cohort and SE definition. Data on all consecutive adult pa-
tients (.16 years) with SE of all etiologies (except postanoxic
SE) admitted to 4 university tertiary care centers were prospec-
tively collected from February 1, 2011, at the Centre Hospitalier
Universitaire Vaudois (Lausanne, Switzerland); from June 1,
2013, at the Brigham and Women’s Hospital and the Massachu-
setts General Hospital (Boston, MA); and from November 1,
2013, at the Beth Israel Deaconess Medical Center (Boston,
MA), all through March 31, 2014. The 3 Boston hospitals are
affiliated with Harvard Medical School and represent here the
HAH (Harvard Affiliated Hospitals) group. Patients from the
Centre Hospitalier Universitaire Vaudois (CHUV) represent
the second group.
Since all patients with suspected SE have an EEGwithin 24 hours
in all centers, patients were screened daily through EEG requests.
Inclusion criteria were checked (V.A. for HAH; A.O.R., J.N. for
CHUV) on a daily basis. The authors have already collaborated on
several projects related to SE,13,14 ensuring a uniform process for data
collection.
SE was defined as an ongoing seizure lasting more than 5 mi-
nutes, or by repeated seizures without complete recovery in-
between.2 In case of nonconvulsive SE, EEG criteria were used.15
Treatment protocol. The 4 hospitals have local treatment pro-
tocols based on current US and European guidelines.2,3 Details
can be found in a previous publication.14 Briefly, a BZD is advo-
cated as first line, with HAH favoring lorazepam or midazolam
and CHUV using preferentially clonazepam. Second, an urgent
seizure-control medication is recommended with a nonsedative
ASD (phenytoin or fosphenytoin, valproic acid, levetiracetam, or
lacosamide). In case of refractory SE, TC using propofol and/or
midazolam, or barbiturates, is recommended, especially for
convulsive SE. In case of a nonconvulsive SE, an additional line
of nonsedative ASD is recommended before considering TC.
Definition of variables. We collected demographics and worst
seizure type (categorized in increasing order of severity as absence
seizures, myoclonic seizures in genetic generalized epilepsy, focal
seizure without or with consciousness impairment, and general-
ized convulsive seizures, or nonconvulsive SE in coma [NCSEC];
generalized convulsive SE and NCSEC were grouped into one
category for analysis, as they represent the 2 most severe types
of seizures). SE severity was assessed using the STESS (Status Ep-
ilepticus Severity Score) for every patient16 ranging from 0 to 6
(see figure e-1 at Neurology.org for more details). Also, for each
patient, the Charlson Comorbidity Index (CCI) was retrieved
based on comorbidities known on admission,17 excluding SE
etiology. CCI is a validated measure based on 17 common
medical conditions with scores ranging from 0 to 33 (see figure
e-2 for more details).
The beginning time for SE was determined using prehospital
charts and emergency department summaries. For SE episodes
without clear onsets (unwitnessed, subtle nonconvulsive SE), the
time last seen well was considered as the beginning of SE. Each
treatment line, including out-of-hospital medication, was prospec-
tively recorded using premedical, emergency, and in-hospital
patient records, including the drug used, total loading (repeated
doses given before introduction of the next line of treatment was
considered as a total loading dose), maintenance dose (highest pre-
scribed dose), and timing of administration. Initial ASD treatment
was considered adequate if local recommendations were followed in
terms of sequence (meaning a BZD first and then a nonsedative
ASD) and in terms of dosage (within a range of 625% of the
recommended dose, as previously described).14 Patients were
counted as having received TC only if CIVADs were used to treat
seizures: use of TC was not considered if CIVADs were adminis-
tered to maintain sedation in a patient intubated for airway pro-
tection, as previously described.12
SE was considered as refractory if persisting despite the first 2
treatment lines.2 It was considered as controlled after the last
clinical or electrical seizure without recurrence for 48 hours, fol-
lowing weaning of sedative medication. Clinical outcome at hos-
pital discharge was assessed using hospital discharge summaries.
All data except for the CCI were prospectively collected.
Primary and secondary outcomes. The rate of TC use was
the primary outcome. Mortality and LOS of survivors in acute
facilities were considered as secondary outcomes.
Standard protocol approvals, registrations, and patient
consents. The institutional review boards of each center
approved this study. Because this observational study involved
no risk for patients and focused on acutely ill patients, consent
was waived.
Statistical analysis. The data were separately summarized for
both groups (CHUV and HAH). Continuous variables were
described by mean and SD, or median and interquartile range,
depending on distribution of variables. Categorical variables were
described by frequencies. The 2 hospital groups were compared
using x2, Wilcoxon rank sum, or Student t tests, as required.
Associations of different clinically relevant variables with the
use of TC and with mortality were assessed using univariate logis-
tic regression. Variables with p value,0.2 (with age, sex, cohort,
or use of TC being forced into models because of primary inter-
est) were entered into a stepwise, backward procedure to fit a mul-
tivariable logistic regression model. A similar analysis was
performed for the duration of hospitalization of survivors, using
a negative binomial regression model. Linearity of continuous
covariates was checked using fractional polynomials.
Model diagnostics were performed as a post estimation step
(influence statistics, deviance residuals, leverages, Pearson or
Hosmer-Lemeshow goodness-of-fit tests, as required). Because
the LOS is greater than zero and attributable to overdispersion,
the negative binomial regression model was compared to the Pois-
son regression model using the countfit Stata command that al-
lows informal assessment of the fit of count models by plotting
observed–predicted vs counts. In addition, likelihood ratio test
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of overdispersion and Vuong test were performed to compare the
2 models. Discrimination was tested using the area under
the receiver operating characteristic (ROC) curve. Results with
a p value ,0.05 were considered statistically significant. Calcu-
lations were performed using Stata version 12 (StataCorp, College
Station, TX).
RESULTS During the study period, 236 SE episodes
in the CHUV and 126 in the HAH were identified.
Both groups were homogeneous in demographics,
comorbidities, SE characteristics, and etiologies
(table 1). Initial treatments were more often in line
with local guidelines at the CHUV than in HAH
(42.8% vs 11.9%), and patients treated in HAH
received significantly more ASDs (3 vs 2) and TC
(25.4% vs 9.75%). However, when TC was used, it
occurred within a similar delay from SE start and after
a similar number of ASDs. Outcomes were similar in
terms of mortality (14% vs 15%) and LOS (10 vs
9 days). Approximately half of the patients (52%) in
the CHUV and more than a third (32.6%) in HAH
were back to their clinical premorbid baseline at hos-
pital discharge.
Table 2 displays associations between the use of
TC and all clinically relevant variables. The multivari-
able logistic regression model shows that TC was
independently associated with younger age, lower
CCI, increasing STESS, SE refractoriness, and hospi-
tal group. This model had an excellent goodness-of-fit
(Hosmer-Lemeshow: p 5 0.859, x2 5 316.8). The
area under the ROC curve was 0.85 (95% confidence
interval 0.80–0.90). Figure 1 displays adjusted mar-
gin probabilities for the use TC by hospital groups,
SE refractoriness, STESS, and CCI (Hosmer-Leme-
show goodness-of-fit test: 0.86): the likelihood of TC
was higher in HAH overall, for refractory SE, for all
STESS between 1 and 5, and for all CCI #4.
Several clinically relevant variables including
demographics and SE characteristics (severity, type
of seizure, etiology, and duration) were significantly
associated with mortality in univariate logistic regres-
sion analysis (table 3). In the multivariate logistic
regression model, increasing CCI and STESS,
a potentially fatal etiology, and refractory SE re-
mained associated with mortality. Of note, the use
Table 1 Cohort description
CHUV (n 5 236) HAH (n 5 126) p Value
Demographic and SE characteristics
Age, median (IQR) 65 (18–89) 60 (25–84) 0.13a
STESS, mean (SD) 2.65 (1.5) 2.62 (1.7) 0.88b
CCI, median (IQR) 1 (0–8) 2 (0–7) 0.35a
Potentially fatal etiology, n (%) 123 (52.1) 66 (52.8) 0.9c
Seizure type, n (%)
Absence 4 (1.7) 1 (0.79)
Focal without consciousness impairment 48 (20.4) 15 (11.9)
Focal with consciousness impairment 71 (30.1) 40 (31.8)
Generalized convulsive 96 (40.7) 52 (41.3)
NCSEC 17 (7.2) 18 (14.3) 0.085c
Treatments
Adequate 1st and 2nd line, n (%) 101 (42.8) 15 (11.9) ,0.001c
Total no. ASDs, median (IQR) 2 (0–5) 3 (1–6) ,0.001a
TC, n (%) 23 (9.8) 32 (25.4) ,0.001c
Delay SE to TC, h, median (IQR) 1.75 (0–24) 1.45 (0–14.6) 0.23a
ASDs before TC, median (IQR) 2 (1–3) 2 (1–3) 0.35a
Outcomes
Mortality, n (%) 33 (14) 19 (15.1) 0.75c
Length of stay of survivors, d, median (IQR) 10 (1–67) 9 (2–58) 0.85a
Abbreviations: ASD 5 antiseizure drug; CCI 5 Charlson Comorbidity Index; CHUV 5 Centre Hospitalier Universitaire
Vaudois; HAH 5 Harvard Affiliated Hospitals; IQR 5 interquartile range; NCSEC 5 nonconvulsive status epilepticus in
coma; SE 5 status epilepticus; STESS 5 Status Epilepticus Severity Score; TC 5 therapeutic coma.
aWilcoxon rank sum test.
bStudent t test.
c Chi-square test.
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Table 2 Clinically relevant variables and their association with the use of TC after univariate and multivariate analyses using logistic regression
Univariate analysis Multivariate analysis
Use of TC No use of TC OR 95% CI p OR 95% CI p
Total 5 362, n (%) 55 (15.2) 307 (84.8)
Demographics
Age, median (IQR) 57 (30–82) 65 (18–79) 0.98 0.96–0.99 0.029 / 0.96 0.94–0.98 0.002
Sex, n (%)
Female 32/170 (18.8) 138/170 (81.2) Ref.
Male 23/192 (12) 169/192 (88) 0.58 0.32–1.04 0.072 / 0.6 0.31–1.17 0.14
CCI, median (IQR) 1 (0–4) 2 (0–8) 0.8 0.69–0.93 0.006 / 0.75 0.62–0.89 0.002
SE characteristics
STESS, mean (SD) 2.96 (1.55) 2.59 (1.61) 1.15 0.96–1.38 0.1 / 2 1.35–3 0.001
Worse type of seizure, n (%)
SP, CP, absence of myoclonic 14/179 (7.8) 165/179 (92.2) Ref.
GC or NCSEC 41/183 (22.4) 142/183 (77.6) 3.4 1.78–6.5 ,0.001
Duration, n (%)
>30 min 301/356 (84.5) 55/356 (15.5)
<30 min 0/6 (0) 6/6 (100) 1
Etiology, n (%)
Premorbid seizures
No 30/188 (16) 158/188 (84) Ref.
Yes 25/174 (14.4) 149/174 (86.6) 0.88 0.49–1.57 0.674
Acute etiology
No 24/154 (15.6) 130/154 (84.4) Ref.
Yes 31/208 (14.9) 177/208 (85.1) 0.94 0.53–1.7 0.85
Potentially fatal etiology
No 30/172 (17.4) 142/172 (82.6) Ref.
Yes 25/189 (13.2) 164/189 (86.8) 0.72 0.4–1.2 0.27
Treatment, n (%)
Center
CHUV 23/236 (9.8) 213/236 (90.2) Ref.
HAH 32/126 (25.4) 94/126 (74.6) 3.15 1.75–5.67 ,0.001 / 11.3 2.47–51.7 0.002
1st and 2nd ASD in line
with guidelines
No 42/246 (17) 204/246 (83) Ref.
Yes 13/116 (11) 103/116 (88) 0.6 0.32–1.2 0.15
Time to treatment
<1 h 26/130 (20) 104/130 (80) Ref.
‡1 h 29/231 (12.5) 202/231 (87.5) 0.5 0.3–1.02 0.06
Refractory SE
No 4/160 (2.5) 156/160 (97.5) Ref.
Yes 51/202 (25.3) 151/202 (74.7) 13.2 4.64–37.34 ,0.001 / 12.3 4.13–36.4 ,0.001
Interaction variable
STESS 3 center / 0.58 0.38–0.9 0.016
Abbreviations: ASD 5 antiseizure drug; CCI 5 Charlson Comorbidity Index; CHUV 5 Centre Hospitalier Universitaire Vaudois; CI 5 confidence interval; CP 5
complex partial; GC 5 generalized convulsive; HAH 5 Harvard Affiliated Hospitals; IQR 5 interquartile range; NCSEC 5 nonconvulsive status epilepticus in coma;
OR 5 odds ratio; Ref. 5 reference group; SE 5 status epilepticus; STESS 5 Status Epilepticus Severity Score; SP 5 simple partial; TC 5 therapeutic coma.
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of TC and the involved center had no influence on
mortality (model goodness-of-fit: p 5 0.43, x2 5
348.8). The area under the ROC curve was 0.76
(95% confidence interval 0.69–0.83).
Details regarding the relationship between selected
variables and the LOS are shown in table 4. After
adjustment for relevant variables using a negative
binomial regression model, increasing STESS,
a potentially fatal etiology, refractory SE, and the
use of TC were significantly associated with longer
hospitalizations. The associated x2 value [chibar2
(01) 5 2178.29, Prob $ chibar2 5 0.000] of the
fitted multivariate model strongly suggests that a is
nonzero and the negative binomial model is more
appropriate than the Poisson model. The offset was
not used. Informal goodness-of-fit was checked by
plotting observed–predicted vs counts.
DISCUSSION This cohort study performed as a natu-
ral experiment shows that there are major differences in
the TC use between the 2 groups. Our study provides
Class III evidence that after controlling for SE severity
and patient comorbidities, TC was much more
frequent in the Boston hospitals as compared to the
Swiss center (adjusted odds ratio: 11.3). While there
was no increase of mortality with TC, it was associated
with increased duration of acute hospitalization.
The difference in TC preference between sites
may be explained by several factors. First, in the con-
text of relatively weak evidence supporting it, there
may be cultural differences and different practice hab-
its across different centers. Observational SE studies
have reported different rates of CIVAD prescription:
5% in Germany,18 8% in Italy,19 10.7%12 in Switzer-
land, 22% in France,20 and up to 31%21 or 36% in
the United States.22 The same is true when describing
treatment of refractory SE: CIVADs were used in
30%23 and 43%24 of patients in Switzerland, as
opposed to 87.3% in the United States.25 Three
recent studies performed in the United States and
Switzerland10–12 have questioned the risk/benefit ratio
of TC, with observational data showing an indepen-
dent association with worse outcome after correction
for major confounders. Nevertheless, more aggressive
treatment, including TC, is recommended by some
experts.26,27 Another explanation may be that the
Figure 1 Adjusted margin probability for using TC comparing the 2 groups: HAH in red and CHUV in blue
(A) Overall probability by groups. (B) Probability by refractory status epilepticus. (C) Probability at equally spaced STESS values. (D) Probability at equally spaced Charl-
son Comorbidity Index values. Vertical axes represent probability of reaching outcome (using TC) based on the multivariate logistic regression model from table 2.
CHUV 5 Centre Hospitalier Universitaire Vaudois; HAH 5 Harvard Affiliated Hospitals; STESS 5 Status Epilepticus Severity Score; TC 5 therapeutic coma.
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Table 3 Clinically relevant variables and their association with mortality after univariate and multivariate analyses using logistic regression
Univariate analysis Multivariate analysis
Survivors Nonsurvivors OR 95% CI p OR 95% CI p
Total 5 362, n (%) 310 (85.6) 52 (14.4)
Demographics
Age, median (IQR) 62 (18–89) 68.5 (26–86) 1.01 0.99–1.03 0.1 / 0.98 0.96–1.01 0.275
Sex, n (%)
Female 147/170 (86.5) 23/170 (13.5) Ref.
Male 163/192 (84.9) 29/192 (15.1) 1.13 0.62–2.05 0.67 / 1.12 0.58–2.14 0.726
CCI, median (IQR) 1 (0–8) 2 (0–7) 1.2 1.07–1.34 0.002 / 1.18 1.04–1.34 0.011
SE characteristics
STESS, mean (SD) 2.49 (1.58) 3.54 (1.46) 1.53 1.25–1.86 ,0.001 / 1.54 1.19–1.99 0.001
Worse type of seizure, n (%)
SP, CP, absence of myoclonic 156/179 (87.1) 23/179 (12.9) Ref.
GC or NCSEC 154/183 (84.1) 29/183 (15.9) 1.27 0.7–2.3 0.81
Duration, n (%)
>30 min 305/356 (85.7) 51/356 (14.3) Ref.
<30 min 5/6 (83.3) 1/6 (16.7) 1.19 0.13–10.44 0.87
Etiology, n (%)
Premorbid seizures
No 152/188 (80.9) 38/188 (19.2) Ref.
Yes 158/175 (90.8) 16/174 (9.2) 0.42 0.22–0.8 0.008
Acute etiology
No 134/154 (87) 20/154 (13) Ref.
Yes 176/208 (84.6) 32/208 (15.4) 1.21 0.66–2.22 0.521
Potentially fatal etiology
No 160/172 (93) 12/172 (7) Ref.
Yes 149/189 (78.9) 40/189 (21.2) 3.57 1.8–7.08 ,0.001 / 2.6 1.25–5.4 0.01
Treatment, n (%)
Center
CHUV 203/236 (86) 33/236 (14) Ref.
HAH 107/126 (84.9) 19/126 (15.1) 1.09 0.6–2 0.78 / 0.79 0.4–1.58 0.518
1st and 2nd ASD in line
with guidelines
No 210/246 (85.4) 36/246 (14.6) Ref.
Yes 100/116 (86.2) 16/116 (13.8) 0.9 0.49–1.76 0.83
Time to treatment
<1 h 115/130 (88.4) 15/130 (11.6) Ref.
‡1 h 194/231 (83.9) 37/231 (16.1) 1.46 0.76–2.78 0.25
Refractory SE
No 147/160 (91.9) 13/160 (8.1) Ref.
Yes 163/202 (80.7) 39/202 (19.3) 2.7 1.38–5.26 0.003 / 2.13 1.01–4.5 0.047
Use of TC
No 266/307 (86.6) 41/307 (13.4) Ref.
Yes 44/55 (80) 11/55 (20) 1.62 0.77–3.39 0.19 / 1.4 0.58–3.39 0.447
Abbreviations: ASD 5 antiseizure drug; CCI 5 Charlson Comorbidity Index; CHUV 5 Centre Hospitalier Universitaire Vaudois; CI 5 confidence interval; CP 5
complex partial; GC 5 generalized convulsive; HAH 5 Harvard Affiliated Hospitals; IQR 5 interquartile range; NCSEC 5 nonconvulsive status epilepticus in coma;
OR 5 odds ratio; Ref. 5 reference group; SE 5 status epilepticus; STESS 5 Status Epilepticus Severity Score; SP 5 simple partial; TC 5 therapeutic coma.
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Table 4 Clinically relevant variables and their association with the length of stay after univariate and multivariate analyses using negative
binomial regression (survivors only)
Univariate analysis Multivariate analysis
Length of stay, d IRR 95% CI p IRR 95% CI p
Total 5 310 survivors, median (IQR) 10 (1–77)
Demographics
Age NA 1 0.99–1 0.7 / 0.99 0.99–1 0.7
Sex, median (IQR)
Female 10 (2–74) Ref.
Male 9 (1–58) 0.86 0.71–1 0.14 / 0.86 0.72–1.03 0.1
CCI NA 1 0.97–1.05 0.5
SE characteristics, median (IQR)
STESS NA 1.1 1.05–1.19 ,0.001 / 1.1 1.02–1.18 0.007
Worse type of seizure
SP, CP, absence of myoclonic 9 (1–58)
GC or NCSEC 10 (2–66) 1.17 0.97–1.42 0.09
Duration
>30 min 10 (1–77) Ref.
<30 min 6 (4–10) 0.63 0.29–1.37 0.25
Etiology, median (IQR)
Premorbid seizures
No 13 (3–67) Ref.
Yes 7 (1–62) 0.62 0.52–0.75 ,0.001
Acute etiology
No 7.5 (1–32) Ref.
Yes 12 (2–77) 1.7 1.41–2.05 ,0.001
Potentially fatal etiology
No 8 (1–45) Ref.
Yes 12 (2–77) 1.56 1.3–1.88 ,0.001 / 1.6 1.34–1.91 ,0.001
Treatment, median (IQR)
Center
CHUV 10 (1–67) Ref.
HAH 9 (2–58) 1.03 0.86–1.25 0.71 / 0.85 0.74–1.04 0.12
1st and 2nd ASD in line with guidelines
No 10 (1–74) Ref.
Yes 9 (2–60) 0.93 0.76–1.15 0.52
Time to treatment
<1 h 9 (2–66) Ref.
‡1 h 10 (1–62) 1.03 0.85–1.25 0.73
Refractory SE
No 9 (1–45) Ref.
Yes 11 (2–74) 1.38 1.15–1.67 0.001 / 1.28 1.06–1.55 0.01
Use of TC
No 9 (1–67) Ref.
Yes 16.5 (4–60) 1.68 1.3–2.2 ,0.001 / 1.6 1.22–2.11 0.001
Abbreviations: ASD5 antiseizure drug; CCI5 Charlson Comorbidity Index; CHUV5 Centre Hospitalier Universitaire Vaudois; CI5 confidence interval; CP5 complex partial;
GC 5 generalized convulsive; HAH 5 Harvard Affiliated Hospitals; IQR 5 interquartile range; IRR 5 incident rate ratio; NA5 not applicable; NCSEC5 nonconvulsive status
epilepticus in coma; Ref. 5 reference group; SE 5 status epilepticus; SP 5 simple partial; STESS 5 Status Epilepticus Severity Score; TC 5 therapeutic coma.
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more frequent inadequacy of initial treatment in
HAH as compared to current guidelines, mostly
attributable to lorazepam underdosing,14 might lead
to an increased need for CIVADs following SE refrac-
toriness. Adequate initial treatment is indeed associ-
ated with more rapid seizure cessation.20 However,
association between use of TC and inadequate initial
ASD was not found, possibly reflecting the confound-
ing action of further treatment. Furthermore, our
group previously showed that treatment inadequacy
has no significant influence on mortality.28 Finally,
the systematic use of continuous EEG in HAH,
which is more common than in Europe, may influ-
ence treatment choices: electrographic seizures could
have been missed in some patients at CHUV, pre-
venting treatment escalation. Breakdown of seizure
types was remarkably similar between the 2 groups,
except that NCSEC was more frequent in HAH,
supporting this hypothesis. However, because tempo-
ral relationships between the start of EEG recordings
and treatment were not recorded, this hypothesis re-
mains unproven.
TC was not associated with mortality after con-
trolling for demographics, SE severity, refractoriness,
and comorbidities but correlated to a 60% increase in
the LOS in acute facilities. Ten years ago, the median
direct cost of an inpatient hospital stay for SE has
been estimated at up to $1,458 US dollars per
day29; any increase in duration of hospital stay may
thus exert an important effect on health care costs.
Mortality was mainly related to SE severity, etiol-
ogy, comorbidities, and refractoriness, in line with
several previous studies,30,31 but not TC. Besides the
aforementioned possible relationship of TC to
increased mortality,10–12 which has been questioned
in view of methodologic limitations,32 one recent
review demonstrated a high rate of infectious compli-
cations after CIVADs (.50%).33 Two other studies
did not show a TC influence on mortality in partic-
ular subtypes of SE—new-onset refractory SE34 and
NCSE.35 Finally, one study modeling decision-
making on the aggressiveness of treatment of non-
convulsive SE in the ICU showed that, even in cases
in which NCSE was thought to cause brain damage,
aggressive treatment may yet confer a greater overall
risk.36 Of interest, a randomized study from India
assessed treatment protocols avoiding CIVADs in
the context of ICU nonavailability37: 92% of patients
with generalized convulsive SE could avoid CIVADs
(used in their protocol as a fifth-line rescue therapy
after failure of BZD and 3 different nonsedative
ASDs); 29% of SE episodes were considered refrac-
tory; and mortality was 13.6% overall and 25.6% for
refractory SE, in line with studies from Western
countries.23,30 As such, there is still a major contro-
versy as to whether TC increases mortality or
improves outcome. TC seems, however, indepen-
dently related to an increased LOS, according to
our data, and infections.12 Because of these consider-
ations, we believe that our findings reinforce the call
for a well-conducted evaluation of the role of TC in
the treatment of SE, going beyond short-term survival
after SE.32
A subset of patients from CHUV included in this
analysis was also part of a previous study showing an
independent increase of mortality associated with the
use of TC.12 When combined with the HAH group,
TC seemed to lose this negative effect. There are
several possible explanations. First, the significant
influence on mortality was strongest for SE types
other than generalized convulsive SE or NCSEC at
the time of treatment in the Swiss study, meaning
that patients with initial generalized convulsive SE
evolving into focal SE were included in the more
benign SE forms for analysis, as opposed to the pres-
ent study, which categorized patients according to the
worst seizure type. Second, the negative effect of TC
may have been lost because more benign forms of SE
with favorable outcome were treated with CIVADs in
HAH as opposed to at CHUV, where TC is usually
reserved for more severe SE. Also, the increase of
mortality associated with TC in the aforementioned
study12 may be attributable to an unrecognized and
as-yet unmeasurable factor influencing mortality and
the clinician’s decision to put a patient in a TC.
Finally, the vast majority of patients in Boston were
treated in a neuro-ICU, as opposed to patients in
Switzerland, treated in a multidisciplinary ICU with
a consultant neurologist. Neurointensivists may be
more aware of systemic complications of CIVADs,
although this probably has a minor role, as a neuro-
ICU vs multidisciplinary ICU setting did not appear
to affect mortality or LOS in SE in a previous study.38
The strengths of this study include the large num-
ber of patients and the first direct comparison of TC
use between 2 geographical settings assessed through
a systematic and comprehensive, prospective data col-
lection. Moreover, statistical models were constructed
in order to strictly include all known relevant out-
come predictors. We acknowledge, however, some
limitations. First, because of the observational design,
we cannot be certain that some unidentified con-
founder influencing the probability of using TC or
mortality was missed. Also, the reasons for death of
patients were not systematically assessed. We also
cannot exclude the possibility that there was a higher
rate of care withdrawal in one group, and we were not
able to evaluate whether death occurred because of
CIVAD side effects. In a dedicated study, while
106 of 120 deaths after SE were primarily related to
the underlying etiology, complications of therapy
were considered to contribute to death in one-third
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of cases.39 Another important limitation of all studies
to date, including this one, is that no one has controlled
for the quality or depth of TC. This limitation is
important in light of evidence that management of
pharmacologically induced coma is highly variable
and often fails to achieve therapeutic targets (i.e.,
EEG burst suppression, seizure suppression, or sup-
pression pattern) (unpublished results of M.B.W.).
The potential benefit of TC may be offset in practice
by adverse effects associated with over- and underdos-
ing of anesthetics. Finally, because functional outcomes
were not assessed based on controlled and validated
scores, the data were not sufficient to determine
whether there was an independent association with TC.
We show that different policies regarding TC
induction for SE management exist, despite relatively
uniform treatment guidelines. The more “aggressive”
and resource-consuming treatment seems to increase
length of hospital stay (and thus costs) without
improvement of survival. This appears highly relevant
in the context of high daily costs related to manage-
ment of acutely ill patients and the increased burden of
SE.40 Based on these findings, we recommend that TC
should be reserved for severe refractory convulsive SE
forms and tailored to the underlying biological back-
ground. Also, every effort should be made to improve
awareness and translation into practice of SE guide-
lines, in order to minimize underdosage of the first
treatment line. Until an urgently needed randomized
trial is performed, SE management should always con-
sider Galen’s principle: primum non nocere.
AUTHOR CONTRIBUTIONS
Dr. Alvarez: drafting/revising the manuscript for content, study concept and
design, analysis and interpretation of data, acquisition of data, statistical anal-
ysis. Dr. Jong Woo Lee: drafting/revising the manuscript for content, acqui-
sition of data, analysis and interpretation of data. Dr. M. Brandon Westover:
drafting/revising the manuscript for content, acquisition of data, analysis and
interpretation of data. Dr. Frank W. Drislane: drafting/revising the manu-
script for content, acquisition of data, analysis and interpretation of data.
Dr. Mohamed Faouzi: drafting/revising the manuscript for content, analysis
and interpretation of data, statistical analysis. Dr. Nicola Marchi: drafting/
revising the manuscript for content, acquisition of data. Dr. Jan Novy: draft-
ing/revising the manuscript for content, acquisition of data. Dr. Barbara A.
Dworetzky: drafting/revising the manuscript for content, acquisition of data.
Dr. Andrea O. Rossetti: drafting/revising the manuscript for content, study
concept and design, analysis and interpretation of data, acquisition of data,
study supervision.
ACKNOWLEDGMENT
The investigators thank Christine Staehli, RN (CHUV), Christine Scott,
R Tech (MGH), and the EEG fellows at times of data acquisition from the
EEG laboratories at the BWH (Swapna Putta and Hong Yu), BIDMC
(Andrew Schomer and Stephen VanHaerents), CHUV (Muriel Tschirren,
Spyridoula Tsetsou, Myriam Guidon, Anita Barbey), and MGH (Kheder
Amar, Yuan Fan, Arash Hadipour Niktarash, Lidia Moura, Marcus Ng,
Deirdre O’Rourke, and Sandipan Pati) for their help in patient identifica-
tion and data collection.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
V. Alvarez was funded by the Swiss National Science Foundation, grant
P2GEP3_148510, and the Gottfried und Julia Bangerter-Rhyner
Foundation during data collection. J. Lee was supported by NINDS
(research funding), Advance Medical and SleepMed/DigiTrace (consultant/
contract work), UCB (research funding). M. Westover was supported by
NIH-NINDS 1K23NS090900, the Rappaport Foundation, the Andrew
David Heitman Neuroendovascular Research Fund. F. Drislane received
honoraria from UpToDate, LWW, and American Academy of Neurology.
J. Novy received travel and speaker honoraries from UCB and Pfizer.
M. Faouzi and N. Marchi report no disclosures relevant to the manuscript.
B. Dworetzky was funded by the Federal Drug Administration, the Ameri-
can Epilepsy Society, and the Epilepsy Foundation. In addition, she is a con-
sultant for SleepMed and for Best Doctors. A. Rossetti received research
support from Sage, UCB, Eisai, and the Swiss National Science Foundation,
grant CR32I3_143780. Go to Neurology.org for full disclosures.
Received December 7, 2015. Accepted in final form May 20, 2016.
REFERENCES
1. Rossetti AO, Lowenstein DH. Management of refractory
status epilepticus in adults: still more questions than
answers. Lancet Neurol 2011;10:922–930.
2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the
evaluation and management of status epilepticus. Neuro-
crit Care 2012;17:3–23.
3. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline
on the management of status epilepticus in adults. Eur J
Neurol 2010;17:348–355.
4. Treiman DM, Meyers PD, Walton NY, et al. A compar-
ison of four treatments for generalized convulsive status
epilepticus. Veterans Affairs Status Epilepticus Coopera-
tive Study Group. N Engl J Med 1998;339:792–798.
5. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramus-
cular versus intravenous therapy for prehospital status epi-
lepticus. N Engl J Med 2012;366:591–600.
6. Young GB, Jordan KG. Do nonconvulsive seizures dam-
age the brain?—yes. Arch Neurol 1998;55:117–119.
7. Aminoff MJ. Do nonconvulsive seizures damage the brain?—
no. Arch Neurol 1998;55:119–120.
8. Claassen J, Taccone FS, Horn P, Holtkamp M,
Stocchetti N, Oddo M. Recommendations on the use of
EEG monitoring in critically ill patients: consensus state-
ment from the neurointensive care section of the ESICM.
Intensive Care Med 2013;39:1337–1351.
9. Wijdicks EF. The multifaceted care of status epilepticus.
Epilepsia 2013;54(suppl 6):61–63.
10. Kowalski RG, Ziai WC, Rees RN, et al. Third-line anti-
epileptic therapy and outcome in status epilepticus: the
impact of vasopressor use and prolonged mechanical ven-
tilation. Crit Care Med 2012;40:2677–2684.
11. Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anes-
thetic drugs in status epilepticus: risk or rescue? A 6-year
cohort study. Neurology 2014;82:656–664.
12. Marchi NA, Novy J, Faouzi M, Stähli C, Burnand B,
Rossetti AO. Status epilepticus: impact of therapeutic
coma on outcome. Crit Care Med 2015;43:1003–1009.
13. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-
line status epilepticus treatment: comparison of phenytoin,
valproate, and levetiracetam. Epilepsia 2011;52:1292–
1296.
14. Alvarez V, Lee JW, Drislane FW, et al. Practice variability
and efficacy of clonazepam, lorazepam, and midazolam in
status epilepticus: a multicenter comparison. Epilepsia
2015;56:1275–1285.
1658 Neurology 87 October 18, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
15. Beniczky S, Hirsch LJ, Kaplan PW, et al. Unified EEG
terminology and criteria for nonconvulsive status epilepti-
cus. Epilepsia 2013;54(suppl 6):28–29.
16. Rossetti AO, Logroscino G, Milligan TA, Michaelides C,
Ruffieux C, Bromfield EB. Status Epilepticus Severity
Score (STESS): a tool to orient early treatment strategy.
J Neurol 2008;255:1561–1566.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new
method of classifying prognostic comorbidity in longitu-
dinal studies: development and validation. J Chronic Dis
1987;40:373–383.
18. Kellinghaus C, Stögbauer F. Treatment of status epilepti-
cus in a large community hospital. Epilepsy Behav 2012;
23:235–240.
19. Vignatelli L, Rinaldi R, Galeotti M, de Carolis P,
D’Alessandro R. Epidemiology of status epilepticus in
a rural area of northern Italy: a 2-year population-based
study. Eur J Neurol 2005;12:897–902.
20. Aranda A, Foucart G, Ducassé JL, Grolleau S,
McGonigal A, Valton L. Generalized convulsive status epi-
lepticus management in adults: a cohort study with evalua-
tion of professional practice. Epilepsia 2010;51:2159–2167.
21. Claassen J, Lokin JK, Fitzsimmons BF, Mendelsohn FA,
Mayer SA. Predictors of functional disability and mortality
after status epilepticus. Neurology 2002;58:139–142.
22. Cook AM, Castle A, Green A, et al. Practice variations in
the management of status epilepticus. Neurocrit Care
2012;17:24–30.
23. Novy J, Logroscino G, Rossetti AO. Refractory status epi-
lepticus: a prospective observational study. Epilepsia 2010;
51:251–256.
24. Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery
from refractory status epilepticus in the intensive care unit:
a 7-year observational study. Epilepsia 2013;54:502–511.
25. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF,
Rabinstein AA. Predictors of outcome in refractory status
epilepticus. JAMA Neurol 2013;70:72–77.
26. Fernandez A, Lantigua H, Lesch C, et al. High-dose mid-
azolam infusion for refractory status epilepticus. Neurology
2014;82:359–365.
27. Riviello JJ, Claassen J, LaRoche SM, et al. Treatment
of status epilepticus: an international survey of experts.
Neurocrit Care 2013;18:193–200.
28. Rossetti AO, Alvarez V, Burnand B, Januel JM. Treatment
deviating from guidelines does not influence status epilep-
ticus prognosis. J Neurol 2013;260:421–428.
29. Penberthy LT, Towne A, Garnett LK, Perlin JB,
DeLorenzo RJ. Estimating the economic burden of status
epilepticus to the health care system. Seizure 2005;14:
46–51.
30. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF,
Hauser WA. Short-term mortality after a first episode of
status epilepticus. Epilepsia 1997;38:1344–1349.
31. Drislane FW, Blum AS, Lopez MR, Gautam S,
Schomer DL. Duration of refractory status epilepticus
and outcome: loss of prognostic utility after several hours.
Epilepsia 2009;50:1566–1571.
32. Hirsch LJ. Finding the lesser of two evils: treating refrac-
tory status epilepticus. Epilepsy Curr 2015;15:313–316.
33. Prabhakar H, Bindra A, Singh GP, Kalaivani M. Propofol
versus thiopental sodium for the treatment of refractory
status epilepticus. Cochrane Database Syst Rev 2012;8:
CD009202.
34. Gaspard N, Foreman BP, Alvarez V, et al. New-onset
refractory status epilepticus: etiology, clinical features,
and outcome. Neurology 2015;85:1604–1613.
35. Uysal U, Quigg M, Bittel B, Hammond N, Shireman TI.
Intravenous anesthesia in treatment of nonconvulsive
status epilepticus: characteristics and outcomes. Epilepsy
Res 2015;116:86–92.
36. Ferguson M, Bianchi MT, Sutter R, et al. Calculating the
risk benefit equation for aggressive treatment of non-
convulsive status epilepticus. Neurocrit Care 2013;18:
216–227.
37. Mundlamuri RC, Sinha S, Subbakrishna DK, et al. Man-
agement of generalised convulsive status epilepticus (SE):
a prospective randomised controlled study of combined
treatment with intravenous lorazepam with either phenyt-
oin, sodium valproate or levetiracetam: pilot study.
Epilepsy Res 2015;114:52–58.
38. Varelas PN, Corry J, Rehman M, et al. Management of
status epilepticus in neurological versus medical intensive
care unit: does it matter? Neurocrit Care 2013;19:4–9.
39. Sokic DV, Jankovic SM, Vojvodic NM, Ristic AJ.
Etiology of a short-term mortality in the group of
750 patients with 920 episodes of status epilepticus within
a period of 10 years (1988–1997). Seizure 2009;18:
215–219.
40. Betjemann JP, Josephson SA, Lowenstein DH, Burke JF.
Trends in status epilepticus-related hospitalizations and
mortality: redefined in US practice over time. JAMA Neurol
2015;72:650–655.
Applications Now Open for 2017 Diversity in
Leadership Program
Applications are now open for the prestigious 2017 AAN Diversity in Leadership Program, which seeks
to identify, orient, and cultivate high-potential members from diverse and underrepresented ethnic back-
grounds who will be lifetime, engaged contributors to the American Academy of Neurology. View qual-
ifications and apply before the December 10 deadline at AAN.com/view/DiversityLeadershipProgram.
Neurology 87 October 18, 2016 1659
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
